ZENITHDRUG Stock Overview
Operates as a pharmaceutical manufacturing and trading company in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Zenith Drugs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹98.70 |
| 52 Week High | ₹154.40 |
| 52 Week Low | ₹52.80 |
| Beta | 0 |
| 11 Month Change | -11.99% |
| 3 Month Change | 21.85% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -6.13% |
Recent News & Updates
Take Care Before Jumping Onto Zenith Drugs Limited (NSE:ZENITHDRUG) Even Though It's 29% Cheaper
Oct 26
The Market Lifts Zenith Drugs Limited (NSE:ZENITHDRUG) Shares 26% But It Can Do More
Aug 30Shareholder Returns
| ZENITHDRUG | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -8.4% | -1.8% | -1.8% |
| 1Y | n/a | 41.2% | 27.2% |
Return vs Industry: Insufficient data to determine how ZENITHDRUG performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ZENITHDRUG performed against the Indian Market.
Price Volatility
| ZENITHDRUG volatility | |
|---|---|
| ZENITHDRUG Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: ZENITHDRUG's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: ZENITHDRUG's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 61 | Sandeep Bhardwaj | zenithdrugs.com |
Zenith Drugs Limited operates as a pharmaceutical manufacturing and trading company in India and internationally. The company offers products in the areas of electrolytes, analgesic, antipyretic, NSAIDs, anti-inflammatory, antiemetic, cold, cough, antihistaminic and antiasthmatic, antibacterial, antifungal, anti-infective, antiparasitic, antiviral, anthelmintic, anti-scabies, antimicrobial, antimalarial, disinfectant, antiseptic, corticosteroids, depigmenting agents, gastrointestinal, liver, kidney, skin care, antibiotic preparations, nutrition supplements, and others. It also provides a range of formulations in various forms, such as ORS powder, liquid orals, ointments, creams, gels, tablets, liquid externals, and capsules.
Zenith Drugs Limited Fundamentals Summary
| ZENITHDRUG fundamental statistics | |
|---|---|
| Market cap | ₹1.69b |
| Earnings (TTM) | ₹95.93m |
| Revenue (TTM) | ₹1.32b |
17.6x
P/E Ratio1.3x
P/S RatioIs ZENITHDRUG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZENITHDRUG income statement (TTM) | |
|---|---|
| Revenue | ₹1.32b |
| Cost of Revenue | ₹855.07m |
| Gross Profit | ₹461.12m |
| Other Expenses | ₹365.20m |
| Earnings | ₹95.93m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.59 |
| Gross Margin | 35.03% |
| Net Profit Margin | 7.29% |
| Debt/Equity Ratio | 39.5% |
How did ZENITHDRUG perform over the long term?
See historical performance and comparison